Rigel Pharmaceuticals (RIGL) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares.
View RIGL analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month target prices for Rigel Pharmaceuticals' shares. Their RIGL share price forecasts range from $1.00 to $15.00. On average, they predict the company's share price to reach $4.21 in the next year. This suggests a possible upside of 169.8% from the stock's current price.
View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts.

Rigel Pharmaceuticals' stock was trading at $1.50 on January 1st, 2023. Since then, RIGL stock has increased by 4.0% and is now trading at $1.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our RIGL earnings forecast.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings results on Tuesday, March, 7th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.08. The biotechnology company had revenue of $51.28 million for the quarter, compared to analysts' expectations of $37.55 million. Rigel Pharmaceuticals had a negative net margin of 34.47% and a negative trailing twelve-month return on equity of 2,419.00%. During the same quarter in the previous year, the company earned ($0.13) EPS.

ETFs with the largest weight of Rigel Pharmaceuticals (NASDAQ:RIGL) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC),

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.80%), BlackRock Inc. (8.13%), Acadian Asset Management LLC (2.14%), State Street Corp (1.98%), Geode Capital Management LLC (1.89%) and FMR LLC (1.63%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez.
View institutional ownership trends.

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RIGL stock can currently be purchased for approximately $1.56.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $270.93 million and generates $120.24 million in revenue each year. The biotechnology company earns $-58,570,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

The company employs 165 workers across the globe.

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101.